So men are dying because they don ’t have women’s brains? Show me the evidence

Mortality rates for prostate cancer are rising, but not because of any neurological determinismIt is the crossover moment. For the first time, more men are dying of prostate cancer than women are from breast cancer. Any GP surgery will offer a blood test to check a man ’s prostate-specific antigen (PSA) indicating cancer. All men have to do is ask.The trouble is that, as we all know, men are from Mars. They don ’t go to GPs, don’t talk about illness and believe in their own invincibility. Men with their compartmentalised brains are inherently greater risk-takers and believe they will beat the odds. In any case, to concede the threat of illness is an acknowledgement of weakness – very unmasculine.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Neuroscience Gender World news Women UK news Cancer Health Society Cancer research Medical research Life and style Feminism Source Type: news

Related Links:

CONCLUSIONS: Our work demonstrates that high levels of PAICS are found in LADC and that this gene may be a potential therapeutic target for this subset of lung cancers. Determining the detailed roles of PAICS in LADC biology may provide useful information for further investigations. PMID: 30641222 [PubMed - as supplied by publisher]
Source: Gene - Category: Genetics & Stem Cells Authors: Tags: Gene Source Type: research
Abstract Tubugi-1 is a small cytotoxic peptide with picomolar cytotoxicity. To improve its cancer cell targeting, it was conjugated using a universal, modular disulfide derivative. This allowed conjugation to a neuropeptide-Y (NPY)-inspired peptide [K4(C-βA-),F7,L17,P34]-hNPY, acting as NPY Y1 receptor (hY1R)-targeting peptide, to form a tubugi-1–SS–NPY disulfide-linked conjugate. The cytotoxic impacts of the novel tubugi-1–NPY peptide–toxin conjugate, as well as of free tubugi-1, and tubugi-1 bearing the thiol spacer (liberated from tubugi-1–NPY conjugate), and native tubulysin A as refe...
Source: Beilstein Journal of Organic Chemistry - Category: Chemistry Authors: Tags: drug targeting neuropeptide Y PDC – drug conjugate targeted tumor therapy tubugi tubulysin A Ugi reaction Full Research Paper Source Type: research
CONCLUSION: This work makes it possible to harmonize the delineation practices around validated standards. An extension to the entire Hauts-de-France region is planned. PMID: 30639377 [PubMed - as supplied by publisher]
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research
Publication date: Available online 8 January 2019Source: Journal of Molecular StructureAuthor(s): Esin Ispir, Mesut Ikiz, Ayşe Inan, Ali Burak Sünbül, Seçil Erden Tayhan, Sema Bilgin, Muhammet Köse, Mahfuz ElmastaşAbstractCo(II), Cu(II) and Zn(II) complexes derived from azo-azomethine compounds were synthesized and characterized by a combination of magnetic susceptibility, elemental analyses, FTIR and UV-Visible spectroscopies. The characterized complexes were found to be mononuclear and the chelation of the ligands to the metal ions occurs through phenolic oxygen and nitrogen atoms of the azomethin...
Source: Journal of Molecular Structure - Category: Molecular Biology Source Type: research
Researchers tested whether the GnRH antagonist degarelix was better at achieving and maintaining ovarian function suppression than the commonly used GnRH agonist triptorelin in premenopausal women with breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer. The finding is based on PROREPAIR-B, a prospective multi-centre observational cohort study that followed up more than 400 patients with metastatic prostate cancer, aimed to identify genetic markers associated with its progression and treatment response. Further studies will evaluate whether patients with BRCA2 mutations can undergo treatments used in patients with ovarian and breast cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
CONCLUSION:: Findings suggest that advanced practice providers can provide survivorship care in accordance with Institute of Medicine standards, which provide a normative standard. This assessment is an important step in evaluating survivorship outcomes. PMID: 30615587 [PubMed - as supplied by publisher]
Source: JOP - Category: Gastroenterology Authors: Tags: J Oncol Pract Source Type: research
By BISHAL GYAWALI MD  Long list of news in lung cancer September was an important month in oncology—especially for lung cancer. The World Conference in Lung Cancer (WCLC) 2018 gave us some important practice-changing results, also leading to four NEJM publications. The trial with most public health impact is unfortunately not published yet. It’s the NELSON trial that randomised more than 15000 asymptomatic people at high risk of lung cancer to either CT-based screening for lung cancer or to no screening and found a significant reduction in lung cancer mortality rates among the screened cohort com...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Research Bishal Gyawali Breast cancer Cancer drugs Clinical Trials health spending immunotherapy Lung cancer Oncology pembrolizumab Source Type: blogs
Radiopharmaceutical therapy involves the use of radionuclides that are either conjugated to tumor-targeting agents (e.g., nanoscale constructs, antibodies, peptides, and small molecules) or that concentrate in tumors through natural physiological mechanisms that occur predominantly in neoplastic cells. In the latter category, radioiodine therapy of thyroid cancer is the prototypical and most widely implemented radiopharmaceutical therapy. In the category of radionuclide-ligand conjugates, antibody and peptide conjugates have been studied extensively. The efficacy of radiopharmaceutical therapy relies on the ability to deli...
Source: Health Physics - Category: Radiology Tags: PAPERS Source Type: research
By CHADI NABHAN MD, MBA, FACP Some books draw you in based on a catchy title, a provocative book jacket, or familiarity with the author. For me, recollections of medical school primers written by the renowned lymphoma pioneer Vincent DeVita Jr. and my own path as an oncologist immediately attracted me to “The Death of Cancer.” I felt a connection to this book before even reading it and prepped myself for an optimistic message about how the cancer field is moving forward. Did I get what I bargained for? Co-authored with his daughter, Elizabeth DeVita-Raeburn, DeVita brings us back decades ago to when he had jus...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health Care Books Physicians Book Review Chadi Nabhan Chemotherapy Oncology randomized controlled trials The Death of Cancer Vincent DeVita Source Type: blogs
More News: Brain | Breast Cancer | Cancer | Cancer & Oncology | Neurology | Neuroscience | Neurosurgery | Primary Care | Prostate Cancer | Research | Science | Women